



ASX ANNOUNCEMENT

30 May 2018

## \$5.2m placement of shares to Fidelity International

**Melbourne, Australia; 30 May 2018:** Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP) ('Cynata') is pleased to announce a A\$5.2 million share placement to Fidelity International ('Fidelity'). Upon completion of the placement, together with their existing equity position, Fidelity's holding in Cynata will increase to approximately 10.0%.

Fidelity is a global asset manager that invests A\$414.5 billion<sup>1</sup> globally on behalf of clients in Asia-Pacific, Europe, the Middle East, and South America. As disclosed on 7 May 2018, Fidelity recently became a substantial holder of Cynata.

Under the placement, Cynata will issue Fidelity with 4,074,320 fully paid ordinary shares in Cynata at an issue price of A\$1.275 per share. This represents a 4.5% premium to Cynata's closing price on Friday 25 May 2018 of A\$1.22. Vesparum Capital is acting in an independent capital markets advisory role for Cynata.

The placement is being made under Cynata's existing 15% placement capacity under ASX Listing Rule 7.1. Funds raised will be used to strengthen Cynata's balance sheet and support the company's continuing product development activities.

Cynata's shares will re-commence normal trading on the ASX on 30 May 2018.

The placement follows Cynata's announcement on Thursday 24 May 2018 that enrolment and dosing for its Phase 1 Clinical Trial of CYP-001 in GvHD has been completed.

Chief Executive Officer and Managing Director of Cynata, Dr Ross Macdonald commented "Fidelity has been a supporter of Cynata for some time now, and we're delighted to have them become one of our largest shareholders. We are pleased that their investment recognises the multiple and significant opportunities available to Cynata and the potential of our Cymerus™ platform to develop stem cell products to treat a wide range of diseases."

<sup>1</sup> As at 31 December 2017

**Ends**

**CONTACTS:** Dr Ross Macdonald, CEO, Cynata Therapeutics, +61 (0)412 119343, [ross.macdonald@cynata.com](mailto:ross.macdonald@cynata.com)  
Daniel Paproth, Australia Media Contact, +61 (0)421 858 982, [daniel.paproth@mcpartners.com.au](mailto:daniel.paproth@mcpartners.com.au)  
Laura Bagby, U.S. Media Contact, 312-448-8098, [lbagby@6degreespr.com](mailto:lbagby@6degreespr.com)



### **About Cynata Therapeutics (ASX: CYP)**

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology addresses a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ utilises induced pluripotent stem cells (iPSCs) to produce a particular type of MSC precursor, called a mesenchymoangioblast (MCA). Cymerus™ provides a source of MSCs that is independent of donor limitations and an “off-the-shelf” stem cell platform for therapeutic product use, with a pharmaceutical product business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics, and provides both a unique differentiator and an important competitive position.

**Cynata Therapeutics Limited**

Level 3, 62 Lygon Street, Carlton, Victoria 3053, Australia  
PO Box 7165, Hawthorn North, Victoria 3122

T: + 613 9824 5254 F: + 613 9822 7735 E: [admin@cynata.com](mailto:admin@cynata.com)

ABN - 98 104 037 372